Help us: Donate
Follow us on:
×

Menu

Back

Tag: Drug Discovery

Researcher hands
A study published in EBioMedicine has shown how a peptide targets and kills senescent cancer cells, potentially paving the way for a new class of interventions. Why we Age: Cellular SenescenceAs your body ages, more of your cells become senescent. Senescent cells do not divide or support the tissues of which they are part; instead,...
Old and young collagen
A recent study published in Aging Cell has turned up potential new therapeutics to target the aging extracellular matrix (ECM). Longevity drug discovery  The discovery of new targets injects fresh lifeblood into the race to develop anti-aging compounds. The strategies used to identify these targets have seen significant innovation recently, with various types of databases...
Unexpected treasure
Researchers have found that zoledronate, a drug used to treat osteoporosis, has unexpected life-extending properties in human beings, and they confirmed these findings in a fruit fly study. The original unexpected findings Zoledronate is a biophosphonate, a drug used to strengthen bones and reduce the risk of osteoporosis-related bone fractures. It is well-absorbed into the...
Quantum computer
With a new announcement from IBM and Germany’s Fraunhofer Institute, the era of quantum computing has finally arrived in Europe. Can its advance speed up the discovery of new drugs? Europe joins the race Despite being a research and manufacturing powerhouse, Germany, like Europe as a whole, has been lagging behind in what is probably...
Deep Longevity
Today, we have a bit more positive news with the announcement that Deep Longevity has added LifeHub and LifeClinic to its network of longevity-focused companies. This company plans to use multiple AI-based biological aging clocks to test a variety of longevity interventions, including supplements, drugs, and lifestyle choices. Teaming up to offer longevity healthcare This...
Dr. João Pedro de Magalhães is a Professor at the University of Liverpool, England, where he studies aging and longevity at the genetic level, and he is also an affiliate Principal Investigator in the Neuroendocrinology and Aging Group at the University of Coimbra, Portugal. Dr. de Magalhães has built the Human Ageing Genomic Resources (HAGR),...